Editing Reduction of Risk Potential (section)

== Monitoring for Adverse Effects and Therapeutic Response ==

Every medication and treatment has both an expected outcome to verify and an adverse effect to watch for. Framing monitoring as a paired question improves both exam performance and clinical safety.

{| class="wikitable"
! Therapy !! Evidence of therapeutic response !! Priority adverse effects to monitor
|-
| Loop diuretic (furosemide) || Weight loss, increased urine output, decreased edema and crackles, improved dyspnea || Hypokalemia, hyponatremia, hypomagnesemia, dehydration, orthostatic hypotension, ototoxicity with rapid intravenous push
|-
| Angiotensin converting enzyme inhibitor || Lower blood pressure, reduced afterload, renal protection in diabetes || Persistent dry cough, hyperkalemia, rising creatinine, angioedema, first-dose hypotension
|-
| Beta blocker || Lower heart rate and blood pressure, less angina || Bradycardia, hypotension, bronchospasm in reactive airway disease, masked hypoglycemia symptoms, fatigue
|-
| Digoxin || Improved cardiac output, fewer heart failure symptoms, rate control || Bradycardia, dysrhythmia, anorexia, nausea, visual halos, toxicity potentiated by hypokalemia
|-
| Warfarin || International normalized ratio in target range, absence of new thrombus || Bleeding: bruising, hematuria, melena, gum or nose bleeding, occult fall in hemoglobin
|-
| Heparin || Activated partial thromboplastin time in target range || Bleeding, heparin-induced thrombocytopenia
|-
| Insulin || Blood glucose and HbA1c toward target || Hypoglycemia, hypokalemia during treatment of ketoacidosis, lipohypertrophy at repeated sites
|-
| Corticosteroid || Reduced inflammation and symptom control || Hyperglycemia, hypertension, immunosuppression with masked infection signs, gastrointestinal bleeding, osteoporosis, adrenal suppression if stopped abruptly
|-
| Opioid analgesic || Reported pain reduction and improved function || Respiratory depression, oversedation, hypotension, constipation, urinary retention
|-
| Antibiotic || Defervescence, falling white blood cell count, resolving local signs || Organ-specific toxicity, allergic reaction, superinfection including Clostridioides difficile and candidiasis
|-
| Bronchodilator || Improved airflow, decreased wheeze, better oxygen saturation || Tachycardia, tremor, palpitations, restlessness
|-
| Antipsychotic || Reduced psychotic symptoms || Extrapyramidal symptoms, neuroleptic malignant syndrome, metabolic effects, QT prolongation
|}

''Note.'' Adapted from Harding et al. (2023), Ignatavicius et al. (2021), and Pagana et al. (2022).

Monitoring principles worth generalizing:

* '''Trend over snapshot.''' A single value rarely decides an action. A hemoglobin that has fallen across three draws matters more than any one number.
* '''Assess the client, not only the monitor.''' Confirm a reading that does not match the client's appearance before acting on it.
* '''Daily weight is the most reliable fluid status measure.''' Weigh at the same time each day, on the same scale, in similar clothing, after voiding. A gain of 1 kilogram corresponds to roughly 1 liter of retained fluid (Potter et al., 2023).
* '''Intake and output plus urine output.''' Adult urine output below roughly 30 mL per hour signals inadequate renal perfusion and warrants reporting (Potter et al., 2023).
* '''Know the antidote.''' Heparin and protamine sulfate, warfarin and vitamin K, opioids and naloxone, benzodiazepines and flumazenil, acetaminophen and acetylcysteine, magnesium and calcium gluconate, digoxin and digoxin immune Fab (Ignatavicius et al., 2021).
* '''Baseline before therapy.''' Renal function before nephrotoxins, hearing before ototoxins, liver enzymes before hepatotoxins, potassium before digoxin, apical pulse before rate-lowering drugs.